Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

REDWOOD CITY, CA, USA I April 14, 2025 I Pheast Therapeutics, a private biotechnology company developing novel therapies to unleash the power of macrophages ...

Pheast Therapeutics has treated the first subject in a multi-centre Phase I trial for the anti-cluster of differentiation 24 (CD24) macrophage checkpoint blocker PHST001, aimed at treating advanced ...

Orthodontic treatments often take years, but a breakthrough discovery could drastically shorten this period. Researchers have uncovered that ATF6, a ...

Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

New methods for deriving macrophages from induced pluripotent stem cells are easier to scale and provide more clinically ...

The polarization response of macrophages seeded on titanium materials is influenced by multiple factors, and artificial intelligence can assist in extracting the key features of implant materials for ...